Alglucosidase alfa

From Wikipedia, the free encyclopedia

Alglucosidase alfa
Systematic (IUPAC) name
 ?
Identifiers
CAS number [1]&rn=1 420794-05-0[1]
ATC code A16AB07
PubChem  ?
Chemical data
Formula C4758H7262N1274O1369S35 
Mol. mass 105338[1]
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.

?
Legal status
Routes  ?

Alglucosidase alfa (Myozyme) is a drug used to treat Glycogen storage disease type II (Pompe's disease).[2] It is an analogue of acid alpha-glucosidase.

Some health plans have refused to pay for Myozyme, because it costs $300,000 a year for adults, and has only been approved by the F.D.A. for use in infants.[3]

[edit] References

  1. ^ a b Website of the American Medical Association
  2. ^ Kishnani PS, Corzo D, Nicolino M, et al (2007). "Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease". Neurology 68 (2): 99–109. doi:10.1212/01.wnl.0000251268.41188.04. PMID 17151339. 
  3. ^ Burden of proof: as costs rise, new medicines face pushback; insurers limit coverage to FDA-approved uses; $300,000 drug denied, by Geeta Anand, Wall Street Journal, Sept. 18, 2007.
Tablets  This pharmacology-related article is a stub. You can help Wikipedia by expanding it.
v • d • e
Other alimentary tract and metabolism products (A16)
Amino acids and derivatives
Enzymes
Various alimentary tract
and metabolism products